Iker Uriarte
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Transcriptomic profiling of epigenetic regulators and metabolic reprogramming in human cholangiocarcinoma.
Journal: Frontiers in cell and developmental biology
Published: December 11, 2025
Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: October 27, 2025
Demonstration of SLU7 as a new cancer target.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 19, 2025
Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through noncanonical SAGA-MYC signaling modulation.
Journal: Hepatology (Baltimore, Md.)
Published: September 10, 2025
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma.
Journal: Cell reports. Medicine
Published: July 27, 2025
Epigenetic mechanisms in HCC immune landscape: Therapeutic implications.
Journal: Seminars in immunology
Published: June 11, 2025
Expression landscape of epigenetic genes in human hepatocellular carcinoma.
Journal: Journal of physiology and biochemistry
Published: April 04, 2025
Quantitative proteomic analysis unveils a critical role of VARS1 in hepatocellular carcinoma aggressiveness through the modulation of MAGI1 expression.
Journal: Molecular cancer
Published: October 31, 2024
Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 28, 2024
FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis.
Journal: Journal of translational medicine
Published: September 14, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).
Journal: Clinical science (London, England : 1979)
Published: June 17, 2024
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
Journal: Gut
Published: May 31, 2024
Last Updated: 09/26/2026